The overview of PMDA activities
|
|
- Lee Greer
- 5 years ago
- Views:
Transcription
1 The overview of PMDA activities Atsushi TAMURA, Ph.D. International Coordination Officer for Medical Devices Pharmaceuticals & Medical Devices Agency
2 Who are we? PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare. Our obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices. We conduct scientific reviews of marketing authorization applications for pharmaceuticals and medical devices, monitoring of their post-marketing safety. We are also responsible for providing relief compensation for sufferers from adverse drug reaction and infections by pharmaceuticals or biological products.
3 PMDA s Mission To provide safer and more effective pharmaceuticals and medical devices as fast as we can 3
4 Philosophy of PMDA PMDA continues to improve the public health and safety of our nation by reviewing applications for marketing approval of pharmaceuticals and medical devices, conducting safety measures, and providing relief to people who have suffered from adverse drug reactions. We conduct our mission in accordance with the following principles: We pursue the development of medical science while performing our duty with greater transparency based on our mission to protect public health and the lives of our citizens. We will be the bridge between the patients and their wishes for faster access to safer and more effective drugs and medical devices. We make science-based judgments on quality, safety, and efficacy of medical products by training personnel to have the latest technical knowledge and wisdom in their field of expertise. We play an active role within the international community by promoting international harmonization. We conduct services in a way that is trusted by the public based on our experiences from the past.
5 Our Responsibilities [MHLW] Ultimate Responsibilities in policies & administrative measures [PMDA] Science base review, examination, data analysis, etc. to assist MHLW S measures
6 PMDA three major functions/tasks PMDA (Phermaceuticals and Medical Devices Agency) was established in April, 2004 to ensure the following 3 tasks to protect public health. Review and Audit for Drugs/ Medical Devices Efficacy and Safety Post- marketing Safety Operations for Drugs / Medical Devices Relief Service for ADR and Other Infectious Disease Clinical Trial Consultation Review of Efficacy and Safety Conformity Audit for Application Materials of GLP,GCP and GMP/QMS Reinforced Safety Information (Database) Scientific Review and Research for Safety Information Information Provision (via the Internet), Pharmaceutical Consultation for Consumers Provision of Medical Expenses, Disability Pensions etc. Relief Service for SMON, HIV-positive and AIDS patients 6
7 Auditor Auditor Key Organization Chart of PMDA Chief Management Officer Offices of General Affairs/ Financial Management Office of Planning and Coordination Office of International Programs Office of Reg. Sci. Operations Senior Executive Director Chief Relief Officer Office of Relief Funds Office of Review Administration Office of Review Management Chief Executive Director (Center for Product Evaluation) Office of New Drug I - V Office of Medical Devices I - III Review Department Office of OTC/Generic Drugs Office of Biologics I - II Executive Director Office of Conformity Audit (Inspections such as GLP/GCP and GPSP) Executive Director Chief Safety Officer Office of Compliance and Standards Office of Safety I - II (GMP/ QMS Inspection) Post-marketing Department 7
8 Contents 1. Organizational Updates 2. Safety Measures 3. PMDA International Vision 4. Regulatory Science 5. Science Board 8
9 1. Organizational Updates Staff Size Strengthen Review System 9
10 PMDA Staff Size Administrative part Safety Department Review Department Planned
11 Strengthen Review System in PMDA- Special Assistant for Chief Executive (Feb. 2012) Office of Review Innovation (Apr. 2012) Science Board (May 2012) 2 Deputy Directors for Center for Product Evaluation (June 2012) 11
12 New Organization (as of June 2012) - Enhance partnership with academia - Subcommittee(Drug) Science Board Subcommittee(Medical Device) Subcommittee(biologics) Subcommittee(cell-and tissue-based products) Office of Review Innovation, Director General Associate director General Deputy Associate director General Executive Director (Review Research) Secretariat Director Director, Center for product evaluation Deputy Center Director for medical Devices Review Section Chief Executive Special Assistant Senior Executive Director (Technology Management) Deputy Center Director for Cellular-and Tissue-based products Safety Section Executive Director (General Coordination) Relief Section Administration Section 12
13 To reduce Drug Submission Lag 1. Promoting Global Clinical Trial Developing Guidelines Holding MRCT Workshop 2. Consultation Pharmaceutical Affairs Consultation on R&D Strategy Prior Assessment Consultation on Drugs 3. Efforts in Regulatory Science Collaboration with Academia Establishment of the Science Board MHLW/PMDA/Academia Collaborative Study
14 2. Safety Measures New Risk Management System Electronic Medical Record Network Project for Drug Safety 14
15 Improving Safety Measures Collection of Information Analysis Assessment of Safety measure effects New Risk management system Planning and Implementation of Safety measures Hypothesis Evaluation of hypothesis Crisis management Goal Prevention of serious drug safety-related crisis from Japan Effective encouragement of proper drug use. Ensuring credibility to post-market safety management system.
16 Electronic Medical Record Network Project for Drug Safety Budget approved FY2011 Governmental to initiate Safety 10Mil. Data project The network construction will be completed by FY2013. Researchers Joint Study Collaboration Data request Collaborative Hospital Database Ethical Committee Network of the Collaborative Hospitals Database Database Quick actions Collaborative study Claim Data Ordering Data Health Records Laboratory Data Database Database Desired Outcomes: Risk & benefit review of medical technologies to provide safer healthcare. Quick and appropriate measures to ensure drug safety.
17 3. PMDA International Vision 17
18 PMDA International vision PMDA EPOCH TOWARD 2020 Concrete goals for PMDA to attain by 2020 as one of world s premier medical products regulatory agencies (Published in November 2011) 18
19 - PMDA EPOCH toward Excellence in Performance 2. Partnership with the Orient 3. Contribution to Harmonization 19
20 4. Regulatory Science MHLW/PMDA/Academia Collaborative Study Regulatory Science Cycle Promotion of Regulatory Science Program of Collaborative Graduate Schools 20
21 MHLW /PMDA /Academia Collaborative Study (MHLW FY 2012 Budget) 1.2B yen (about $15M US) Establishment of evaluation methods for safety and efficacy based on Regulatory Science Enhancement of personnel exchange among PMDA, Research Institutes, NIHS MHLW Support Research Intuitions Personnel exchange 366M yen (about $4.6M US) for; Developing guidance for innovative drug/medical device/biologics to streamline review process NIHS Develop Guidelines Cultivate Human Resource
22 Regulatory Science Cycle Advanced RS Data Acquisition Scientific Reflection Evaluation & Estimation Regulatory Action Balancing Factors 22
23 Promotion of Regulatory Science Policy recommendations released in 2011 Committee on Pharmaceutical of Science, Science Council of Japan (August 19, 2011) Regulatory Science is seen as Science that adjusts science technology outcome to it s most favorable shape in harmonization between human and society that is an essential concept to prove risk/benefit and to ensure safety of pharmaceuticals and medical devices. Target for Drug discovery Drug discovery by Academia Seeds Discovery Lead compounds Identification Optimization Valley of Death Non-clinical Trial Clinical Trial License out to Industry R&D by Industry For Developments Eying their Exits(Practical Use), for Rapid Processes Leading Collaboration to Practical Use, and for Ensuring the Efficacy and Safety with Academia Promotion of Regulatory Science Research is Essential 23
24 Program of Collaborative Graduate Schools Agreement with 12 Universities (as of June, 2012) Yamagata University Musashino University University of Tsukuba Kobe University Shujitsu University Osaka University Gifu Pharmaceutical University Gifu University Chiba University Teikyo University Yokohama City University Shizuoka Prefectural University 24
25 5 Establishment of the Science Board 25
26 Why Science Board now? With Review Goal (Time) achieved and Staffers increasing, We at PMDA are required to: 1 Provide review and consultation services with understanding of advanced technologies (antibody-based drugs, companion diagnostic drugs, ventricular assist devices, regenerative medicine, cancer vaccines, etc.). 2 Provide consultation/advice on the advanced scientific technology from the early stage of development to deliver the medicinal products utilizing advanced technologies sooner to the medicinal scene. 3 Keep close relationship with the academia to have the PMDA reviewers updated to the accelerating innovation. Science Board 26
27 Science Board and Office of Review Innovation Office of Review Innovation Director General Science Board Committee members: External experts from Academia Not involved in the Review Process of individual products Secretariat Director Secretariat Director s office Mission Reform PMDA reviews and related services based on science with consideration for actual medical practices Associate Director General Committee 1 Review policy for innovative medical products 2 Development of guidelines 3 Regulatory Science Research 4 Personnel exchanges 5 Election of External review experts 6 Improvements in the scientific aspects of review Subcommittee PMDA Offices Review Safety Deliberation on problems in each field Collaboration with PMDA working team (RS research, guideline development, etc.) Pharmaceuticals Medical Devices Bio-based products Cell- & tissue- Based products RS SGD RS: Office of Regulatory Science SGD: Office of Standards and Guidelines Development 27
28 Basic Research Seeds of new drug / medical devices originated in Japan For PMDA To Be More Science-Based Quality Tests Non-clinical tests Pharmaceutical consultation on R&D Strategy Office of Review Innovation Establishment of the Science Board The Science Board was established in May 2012 to discuss how PMDA can better cope with products with advanced scientific technology, in each developmental stage such as basic research, development support, product review, and post market safety measures. CT Clinical Trial Consultation Review Review Approve Post Marketing Post Marketing Safety Measure Offices of Review (Drugs & Medical Devices), Office of Safety Practical use Innovative medical products Board members Academia 28
29 To Improve Public Health Review Safety Relief 29
30 Thank you for your attention! URL: Atsushi TAMURA, Ph.D. International Coordination Officer for Medical Devices Pharmaceuticals & Medical Devices Agency JAPAN ( 独 ) 医薬品医療機器総合機構国際業務調整役 ( 医療機器担当 ) 田村敦史 東京都千代田区霞ヶ関 TEL 03(3506)9456 FAX 03(3506)
Mid-term Targets of the Pharmaceuticals and Medical Devices Agency (PMDA) *(Provisional Translation)
Mid-term Targets of the Pharmaceuticals and Medical Devices Agency (PMDA) *(Provisional Translation) * This translation of the original Japanese text is for information purposes only (in the event of inconsistency,
More informationPMDA Update: Its current situation
PMDA Update: Its current situation and future direction Tatsuya Kondo, M.D. Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA), Japan 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam
More informationRole and Vision of PMDA
Role and Vision of PMDA ~Promoting Global Public Health~ Taisuke Hojo Senior Executive Director Pharmaceutical and Medical Devices Agency (PMDA) 1 st Malaysia-Japan Symposium March 10 th, 2015 Today s
More informationDirect Patient ADR reporting system in Japan. Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Direct Patient ADR reporting system in Japan Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan Disclaimer The views and opinions expressed in the following PowerPoint
More informationGCP Inspection by PMDA
2012 EU GCP Inspectors Working Group Workshop London, 12-14 November 2012 Practical Experience in GCP inspections, non EU/EEA countries GCP Inspection by PMDA Kazuko Natsui Inspector for GCP Inspection,
More informationTomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan
Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan The views presented in this presentation are those of the author and should not be understood or quoted as being made
More informationForward looking approaches & its Experiences of PMDA's ATC
6 th Asia Partnership Conference of Pharmaceutical Associations, Tokyo, 5 th April 2017 Forward looking approaches & its Experiences of PMDA's ATC Junko Sato, PhD Office Director, Office of International
More informationII. OPERATION RESULTS / ACHIEVEMENT OF FY 2005
II. OPERATION RESULTS / ACHIEVEMENT OF FY 2005 PART 1. IMPROVEMENT IN OVERALL OPERATIONS AND SERVICE QUALITY OF THE AGENCY (1) Development and Implementation of 2005 Fiscal Year Plan The Agency is required
More informationCurrent status on Adverse Event Reporting in Japan
Current status on Adverse Event Reporting in Japan Iku Mitta Safety Reports Management Division, Office of Safety I PMDA 1 Abbreviation ADR: Adverse Drug Reaction DB: Database EPPV:Early Post-Marketing
More informationPMDA EPOCH Toward 2020
PMDA International Vision PMDA EPOCH Toward 2020 As one of the world s top three medical products regulatory agencies comparable to its American and European counterparts, PMDA aims to: 1. Secure the highest
More informationPost Market Surveillance and Vigilance in Japan. Medical Device Safety Division, Office of Safety I
Post Market Surveillance and Vigilance in Japan Medical Device Safety Division, Office of Safety I 1 Overview of Adverse Event Reporting 医療機関 Healthcare professionals /facilities 2. Investigation 3. Investigation
More informationWhy do we need an addendum to ICH E6?
Addendum to ICH E6 Hideaki Ui, Ph.D. Inspection Director Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency, Japan Disclaimer The views and opinions expressed in
More informationHow Will Patient Centricity be Captured in the Japanese HTA and Healthcare Reform? View from the Japanese Academia Side
How Will Patient Centricity be Captured in the Japanese HTA and Healthcare Reform? View from the Japanese Academia Side Shunya Ikeda, MD International University of Health and Welfare 患者中心 Kanja-chushin
More informationMedical Innovation as a National Strategy
Medical Innovation as a National Strategy March 18, 2013 Hideaki Nakagaki Deputy General, Office of Healthcare Policy Cabinet Secretariat Provisional Translation 1 Establishment of Office of Healthcare
More informationInternational trend on medical device regulatory convergence
International trend on medical device regulatory convergence Mari Shirotani, Ph.D. Division Director, Office of International Programs Pharmaceuticals and Medical Devices Agency (PMDA) 1st December, 2017
More informationTraining components for GCP. inspectors in PMDA. Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA
Training components for GCP inspectors in PMDA Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA Content 1. Conformity inspection in the training program for newcomers to PMDA 2. The training
More informationQuality Risk Management ICH Q9
Quality Risk Management ICH Q9 Executive summary for competent authorities and industry Disclaimer: This presentation includes the author s views on quality risk management theory and practice. The presentation
More informationSection 3. Organization of the MOD/SDF
Part II The Basics of Japan s Defense Policy Section 3. Organization of the MOD/SDF The Self-Defense Forces (SDF), the core of Japan s defense capability, is a specialist organization that plays the most
More informationReform of Japan s Nuclear Safety Regulation
Reform of Japan s Nuclear Safety Regulation January, 2012 The nuclear accident at TEPCO s Fukushima Dai-ichi Nuclear Power Stations severely damaged society, economy and people s mind. Especially in Fukushima
More informationPharmacovigilance: The patient s Perspective. Souzi Makri Chairperson AGORA EUPATI Fellow Executive Secretary CYPLAR President ENFA
Pharmacovigilance: The patient s Perspective Souzi Makri Chairperson AGORA EUPATI Fellow Executive Secretary CYPLAR President ENFA Scope of presentation Why is Pharmacovigilance important for patients?
More informationEvaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare
Notification number: 0427-1 April 27, 2015 To: Prefectural Health Department (Bureau) Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Notification
More informationPoints to Consider regarding the Notification and Publication of Package Insert Language
Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Safety Division, Pharmaceutical Safety and Environmental Health Office of Safety I Bureau This English version
More informationDevelopment and Promotion of Nursing-Care Robots
July, 16, 2017 Development and Promotion of Nursing-Care Robots Japan Robot Revolution Policy and its Impact on the Application of Robots in Elderly Care Takeshi Kobayashi Senior Officer for welfare equipment
More informationNew Streams of Risk Management. Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA)
New Streams of Risk Management Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are
More informationGuidelines for Conflict of Interest Issues Related to Clinical Studies in Artificial Organs. Attached Documents
Guidelines for Conflict of Interest Issues Related to Clinical Studies in Artificial Organs Attached Documents 1. Guidelines for Conflict of Interest Issues Related to Clinical Studies in Artificial Organs
More informationInvitation to Apply for Partnering Forum 2007
Invitation to Apply for Partnering Forum 2007 We are proud to announce that The International Life Science Partnering Forum KOBE/HYOGO 2007, which is an International Business Match Making Event for life
More informationLaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S.
LaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S. Food and Drug Administration 1 Office of the Commissioner
More informationAST Research Network Career Development Grants: 2019 Faculty Development Research Grant
AST Research Network Career Development Grants: 2019 Faculty Development Research Grant The application deadline is 11:59 pm Pacific Standard Time on Wednesday, November 1, 2018. A limited number of grants
More informationFINAL STATEMENT BY THIRD APEC HIGH LEVEL MEETING ON HEALTH AND THE ECONOMY
FINAL STATEMENT BY THIRD APEC HIGH LEVEL MEETING ON HEALTH AND THE ECONOMY The third APEC High Level Meeting on Health and the Economy (HLM3) was held in Nusa Dua, Bali, Indonesia, on 24-25 September 2013.
More informationEuropean IVD Regulations and Risk Based Classification. An Overview for Global Quality Professionals
European IVD Regulations and Risk Based Classification An Overview for Global Quality Professionals Anna Sadio IVD Technical Expert/Project Manager Oct 2013 Caution The new regulations are draft and subject
More informationMRC Funding and Translational Research. Dr Catriona Crombie
MRC Funding and Translational Research Dr Catriona Crombie Medical Research Council The Medical Research Council is dedicated to improving human health through the best scientific research. Its work, on
More informationQuality Assurance and Regulatory Compliance Office and USAMRIID FDA Risk Management. Carolyn Mentzer Chief, QARCO
Quality Assurance and Regulatory Compliance Office and USAMRIID FDA Risk Management Carolyn Mentzer Chief, QARCO 301-619-3422 Who We Are and What We Do USAMRIID s mission is to conduct basic and applied
More informationLEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS
LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS Joey Gouws MCC and Cluster: Food Control, Pharmaceutical Trade and Product Regulation NATIONAL DEPARTMENT OF HEALTH
More informationProfessional Student Outcomes (PSOs) - the academic knowledge, skills, and attitudes that a pharmacy graduate should possess.
Professional Student Outcomes (PSOs) - the academic knowledge, skills, and attitudes that a pharmacy graduate should possess. Number Outcome SBA SBA-1 SBA-1.1 SBA-1.2 SBA-1.3 SBA-1.4 SBA-1.5 SBA-1.6 SBA-1.7
More informationUC HEALTH. 8/15/16 Working Document
1) UC Health Mission Our mission is to make health care better. Each UC health system works to advance this mission in its community and as a system of health systems, we work together to catalyze innovation
More informationo o o o o 2014 Application Form Congratulations, you have been selected to apply for the Lilly Innovation Fellowship Award. This is a competitive Award program designed to identify, recognize
More informationAST Research Network Career Development Grants: 2019 Fellowship Research Grant
AST Research Network Career Development Grants: 2019 Fellowship Research Grant The application deadline is 11:59 pm Pacific Standard Time on Wednesday, November 1, 2018. A limited number of grants are
More informationActivities of the Japan Medical Association Team in Response to the Great East Japan Earthquake
Conferences and Lectures Special Feature: JMA Symposium on Health Policy Disaster Medicine and Medical Associations Activities of the Japan Medical Association Team in Response to the Great East Japan
More informationEuropean Patients Academy (EUPATI) Update
European Patients Academy (EUPATI) Update EMA meeting with patient/consumer organisations 11 Dec 2013 Maria Mavris EURORDIS // EUPATI WP4 Co-Lead For patient-centric medicines R&D and to contribute to
More informationInformation Brochure Professional Certificate in Pharmacovigilance
Information Brochure Professional Certificate in Pharmacovigilance Catalyst Clinical Services Pvt. Ltd. Unit No. 11, CSC-12, Block D1, Sector-16, Rohini, Delhi - 110089 (India) M: +91 9818356273 Email:
More informationSpecial session on Ebola. Agenda item 3 25 January The Executive Board,
Special session on Ebola EBSS3.R1 Agenda item 3 25 January 2015 Ebola: ending the current outbreak, strengthening global preparedness and ensuring WHO s capacity to prepare for and respond to future large-scale
More informationUMMS / UMMHC Academic Health Sciences Center
UMMS / UMMHC Academic Health Sciences Center Joint Strategic Plan 2014 2020 FINAL DRAFT August 21, 2014 We are a leading academic health sciences center, consisting of the University of Massachusetts Medical
More informationWHO's response to the Fukushima Daiichi NPP accident (2012) Seminar on the recovery and reconstruction of Fukushima, 3 September 2014, Geneva
WHO's response to the Fukushima Daiichi NPP accident (2012) 1 Seminar on the recovery and reconstruction of Fukushima, 3 September 2014, Geneva WHO's role in Radiation Emergency Response WHO Constitution
More information2018 Request for Applications for the following two grant mechanisms Target Identification in Lupus Program & Novel Research Grant Program
2018 Request for Applications for the following two grant mechanisms Target Identification in Lupus Program & Novel Research Grant Program Release Date: November 3, 2017 Application Due Date: February
More informationSITUATION ANALYSIS OF HTA INTRODUCTION AT NATIONAL LEVEL. Instruction for respondents
SITUATION ANALYSIS OF HTA INTRODUCTION AT NATIONAL LEVEL What is the aim of this questionnaire? Instruction for respondents Every country is different. The way that your health system is designed, how
More informationPublic health, innovation and intellectual property: global strategy and plan of action
EXECUTIVE BOARD EB126/6 126th Session 3 December 2009 Provisional agenda item 4.3 Public health, innovation and intellectual property: global strategy and plan of action Report by the Secretariat 1. The
More informationRegulatory Control of Diagnostics in Tanzania. Hiiti Sillo Ag. Director General Tanzania Food and Drugs Authority
6 th Consultative Stakeholders Meeting on UN PQ of Medicines, Diagnostics and Vaccines 4-5 April, 2011, Geneva, Switzerland Regulatory Control of Diagnostics in Tanzania Hiiti Sillo Ag. Director General
More informationConsideration on Global Harmonization
ICDRA Workshop I Consideration on Global Harmonization Oct. 25, 2012 Dr. Nobumasa Nakashima Director, Office of International Programs PMDA, Japan 1 Current Harmonization Activities ICH: International
More informationKnowledge Cluster Initiative
Knowledge Cluster Initiative -present state & issues- Yasushi Taguchi Director Office for the promotion of Regional R&D Activities Science and Technology Policy Bureau MEXT Ministry of Education, Culture,
More informationETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM
ETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM Outline Introduction Composition Responsibilities of IEC Responsibilities
More informationContent Sheet 11-1: Overview of Norms and Accreditation
Content Sheet 11-1: Overview of Norms and Accreditation Role in quality management system Assessment is the means of determining the effectiveness of a laboratory s quality management system. Standards,
More informationAudits/Inspections Be Prepared for Anything
Audits/Inspections Be Prepared for Anything Practices, laboratories, institutions, and clinics that participate in clinical trials are subject to audits by a number of different entities. As a primary
More informationPharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective
Pharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan Disclaimer The views and opinions
More informationBreak the cultural Great Wall. By Rong Hui Gao M.D. MBA 25 Feb, 2010
Break the cultural Great Wall By Rong Hui Gao M.D. MBA 25 Feb, 2010 1 East Meets West 礼 Respect 信 Trust 求同 Homogeneous 关系 Relationship 领导力 Leadership 创新 Innovation 求异 Individuality 信誉 Credibility 2 China
More informationHigh Level Pharmaceutical Forum
High Level Pharmaceutical Forum 2005-2008 Final Conclusions and Recommendations of the High Level Pharmaceutical Forum On 2 nd October 2008, the High Level Pharmaceutical Forum agreed on the following
More information12.0 Investigator Responsibilities
12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement, the investigational
More informationRoles & Responsibilities of Investigator & IRB
Roles & Responsibilities of Investigator & IRB Jaranit Kaewkungwal Mahidol University Regulatory & Guidelines Regulatory & Guidelines GCP & Computer / Database Management Systems International Conference
More informationHEALTH POLICY, LEGISLATION AND PLANS
HEALTH POLICY, LEGISLATION AND PLANS Health Policy Policy guidelines for health service provision and development have also been provided in the Constitutions of different administrative period. The following
More informationJesuits maintain the largest, most extensive and oldest higher education system in the world
For 450 years Pontifical Gregorian University Rome, Italy (1551) Messina Sicily (1548) St. Paul's College Macau, China (1594) Medical College Bahia, Brazil (1556) St. Paul's College Goa, India (1542) Jesuits
More informationSTUDY PLAN Master Degree In Clinical Nursing/Critical Care (Thesis )
STUDY PLAN Master Degree In Clinical Nursing/Critical Care (Thesis ) I. GENERAL RULES AND CONDITIONS:- 1. This plan conforms to the valid regulations of the programs of graduate studies. 2. Areas of specialty
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More informationContributing to the World Peace and Promoting Effective Security Export Control CENTER FOR INFORMATION ON SECURITY TRADE CONTROL
Contributing to the World Peace and Promoting Effective Security Export Control CENTER FOR INFORMATION ON SECURITY TRADE CONTROL CISTEC Spirit Creativity International Sp Contents Introduction 1 History
More informationMission. History. Cleared for public release. SAF/PA Case Number
U.S. Air Force Scientific Advisory Board The U.S. Air Force Scientific Advisory Board (SAB) is a Federal Advisory Committee chartered by the Secretary of Defense that consists of civilian experts appointed
More informationPablo Tebas, M.D. Joseph Quinn, RN, BSN Yan Jiang, RN, BSN, MSN
Gilead Sciences, Inc. / Protocol Number GS-US-380-1489 Page 1 of 9 PARTNER PREGNANCY FOLLOW UP CONSENT FORM Sponsor / Study Title: Protocol Number: Principal Investigator: (Study Doctor) Gilead Sciences,
More informationTrends in the development of regulatory systems by the example of ICH countries
Trends in the development of regulatory systems by the example of ICH countries Author: Pär Tellner, Member of ICH Management Committee (ICH MC), EFPIA * Date: 27/08/2018 * GMP conference, Kazan, Russia
More informationNSF: Form and Function
NSF: Form and Function C. Susan Weiler Office for Earth System Studies Whitman College DISCCRS VII Symposium, Colorado Springs, CO, October, 2012 Vannevar Bush and Science: The Endless Frontier A Report
More informationGAO ANTHRAX VACCINE. Changes to the Manufacturing Process. Testimony
GAO United States General Accounting Office Testimony Before the Subcommittee on National Security, Veterans Affairs, and International Relations, Committee on Government Reform, House of Representatives
More informationHelping physicians care for patients Aider les médecins à prendre soin des patients
CMA s Response to Health Canada s Consultation Questions Regulatory Framework for the Mandatory Reporting of Adverse Drug Reactions and Medical Device Incidents by Provincial and Territorial Healthcare
More informationTowards Quality Care for Patients. National Core Standards for Health Establishments in South Africa Abridged version
Towards Quality Care for Patients National Core Standards for Health Establishments in South Africa Abridged version National Department of Health 2011 National Core Standards for Health Establishments
More informationThe Australian Pancreatic Cancer Genome Initiative (APGI)
The Australian Pancreatic Cancer Genome Initiative (APGI) BioSpecimen & Data Access Policy Version 4.4 Scope: This policy covers all requests for access to BioSpecimens and clinical data managed by the
More informationBrooks College of Health Nursing Course Descriptions
CATALOG 2010-2011 Undergraduate Information Brooks College of Health Nursing Course Descriptions NSP3486: AIDS: A Health Perspective 3 This course provides a comprehensive view of the spectrum of HIV infection
More informationPublic Health Subcommittee
Public Health Subcommittee Decision Brief: Improving Defense Health Program Medical Research Processes Defense Health Board June 26, 2017 1 Overview Tasking Membership Timeline Findings & Recommendations
More informationAction Plan for Strengthening Measures on Emerging Infectious Diseases (Outline)
Action Plan for Strengthening Measures on Emerging Infectious Diseases (Outline) Spread of Ebola Virus Disease in West Africa A significant impact on people s daily lives and economic activities
More informationDetailed planning for secure health care delivery
Detailed planning for secure health care delivery Country: Japan Partner Institute: Kinugasa Research Institute, Ritsumeikan University, Kyoto Survey no: (9)2007 Author(s): Matsuda, Ryozo Health Policy
More informationLegislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018
Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018 Dr. Rania Bader, HRH2030 Health Workforce Competency Lead HRH2030 The Human Resources for Health (HRH2030) is a
More informationNEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use EMEA/267187/2005/ Rev. 1 London, 26 April 2006 NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE The CPMP/CHMP
More informationQuality Improvement Plan
Quality Improvement Plan Agency Mission: The mission of MMSC Home Care Plus is to at all times render high quality, comprehensive, safe and cost-effective home health care and public health services to
More informationNurse Practitioner Student Learning Outcomes
ADULT-GERONTOLOGY PRIMARY CARE NURSE PRACTITIONER Nurse Practitioner Student Learning Outcomes Students in the Nurse Practitioner Program at Wilkes University will: 1. Synthesize theoretical, scientific,
More informationISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan
ISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan What is GCP? Good Clinical Practice (GCP) is an international
More informationLeadership and Cesarean Section Reduction. Funding for the development of this toolkit was provided by the California Health Care Foundation
Leadership and Cesarean Section Reduction Funding for the development of this toolkit was provided by the California Health Care Foundation The California Health Care Foundation is dedicated to advancing
More informationSOP: New Revised Reviewed Effective Date: 08 October Approved by : Supervisor/Manager Risk/Ethics Sr. Mgmt Committees Board/Councils
Title: Assessment of Study Feasibility Manual: RI MUHC Policies and Procedures Human Research SOPs Originating Dept/ Service: RI MUHC Division of Clinical Research SOP: New Revised Reviewed Effective Date:
More informationFDA Outlook Seth A. Mailhot, Partner Lead, FDA Regulatory Practice
FDA Outlook 2017 Seth A. Mailhot, Partner Lead, FDA Regulatory Practice January,25, 2017 Overview Gaming the Elections Influence on FDA in 2017 Potential Congressional Activity PDUFA VI and MDUFA IV Restructuring
More informationImpact the World: Human Health President s Report to the Board of Trustees November 10, 2017
Impact the World: Human Health President s Report to the Board of Trustees November 10, 2017 Penn State s Vision To be a leader in promoting quality of life through comprehensive approaches to enhancing
More informationCFP in Japan -New step for privatization of CFP program-
CFP in Japan -New step for privatization of CFP program- Asami Miyake Japan Environmental Management Association for Industry (JEMAI) 17 April, 2012 PCF World Summit Today s contents Introduction of JEMAI
More informationTARGETED RFA IN PROSTATE CANCER RESEARCH Predictive Markers
TARGETED RFA IN PROSTATE CANCER RESEARCH Predictive Markers Revised 20180504 *see p. 3 sentence revised Part 1: Overview Information Participating Organization(s) Funding Opportunity Title Description
More informationWORLD HEALTH ORGANIZATION
WORLD HEALTH ORGANIZATION EXECUTIVE BOARD EB115/6 115th Session 25 November 2004 Provisional agenda item 4.3 Responding to health aspects of crises Report by the Secretariat 1. Health aspects of crises
More informationHealth care innovations and medical technology: reaching the unreached
Health care innovations and medical technology: reaching the unreached Context setting India ill equipped to meet the growing needs of the population. Brilliance and talent in medicine, engineering & basic
More informationCoastal Medical, Inc.
A Culture of Collaboration The Organization Physician-owned group Currently 19 offices across the state of Rhode Island and growing 85 physicians, 101 care providers The Challenge Implement a single, unified
More informationFederal Research: Neuroscience and the BRAIN Initiative
Federal Research: Neuroscience and the BRAIN Initiative Lewis-Burke Associates, LLC June 1,2017 About Lewis-Burke Twenty-eight policy experts with range of expertise/backgrounds allow multi-layered issue
More informationAREA STUDIES JAPAN Protection and Promotion of Human Health in Japan - R. Kishi, J. Goshima and A. Isu
PROTECTION AND PROMOTION OF HUMAN HEALTH IN JAPAN R. Kishi, J. Goshima and A. Isu Department of Public Health, Hokkaido University School of Medicine, Japan Keywords: administrative reform, decentralization,
More informationWYSIWYG CO., LTD. October 2015
WYSIWYG CO., LTD. October 2015 CEO GREETINGS WysiWyg, since its foundation in 1994 and NASA database preparation to the present day, has always endeavored to achieve customer satisfaction with high quality
More informationCONSENSUS FRAMEWORK FOR ETHICAL COLLABORATION
CONSENSUS FRAMEWORK FOR ETHICAL COLLABORATION November 2016 ABOUT CORD The Canadian Organization for Rare Disorders (CORD) provides a strong common voice to advocate for health policy and a healthcare
More informationREPORT ON DRUG REGULATORY SYSTEM ASSESSMENT OF MONGOLIA
REPORT ON DRUG REGULATORY SYSTEM ASSESSMENT OF MONGOLIA ULAANBAATAR 2011 Abbreviations... 3 Acknowledgement... 4 Executive Summary... 5 1. General information on the assessment.... 7 1.1 Purpose of this
More informationDr Nata Menabde. Candidate for WHO Regional Director for Europe. Excellence for Health and Equity
Dr Nata Menabde Candidate for WHO Regional Director for Europe Excellence for Health and Equity A message from Dr Nata Menabde With this message, I would like to let you know of my candidacy for the position
More informationCommission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics Oslo
Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics 30.1.2017 Oslo 3.2.2017 O. Konttinen 1 Background Based on directive 2001/20/EC of the clinical trials on medicinal
More informationPHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR REVIEW/EVALUATION CLINICAL TRIAL APPLICATIONS FOR VACCINES AND BIOLOGICALS MALAWI
PHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR REVIEW/EVALUATION OF CLINICAL TRIAL APPLICATIONS FOR VACCINES AND BIOLOGICALS IN MALAWI 1. INTRODUCTION The clinical trial application must undergo a
More informationNFMRI. National Foundation for Medical Research and Innovation. Impact giving Advancing medical innovations
NFMRI National Foundation for Medical Research and Innovation Impact giving Advancing medical innovations Philanthropy has the freedom to think different, do different, & make a difference. Medical innovation
More informationStrategies to Improve the Use of Medicines Standard Treatment Guidelines
Strategies to Improve the Use of Medicines Standard Treatment Guidelines Review of the Cesarean-section Antibiotic Prophylaxis Program in Jordan and Workshop on Rational Medicine Use and Infection Control
More informationNew European Union Clinical Trial Regulations
New European Union Clinical Trial Regulations Incorporate Monitoring and Safety Reporting Techniques into U.S. and EU Clinical Trial SOPs Anita K. Murthy Deputy Director, Global Regulatory Affairs Bayer
More informationNovember Innovative Medicines Initiative (IMI) Intellectual Property (IP) Policy. Guidance Note for IMI Applicants and Participants
Innovative Medicines Initiative (IMI) Intellectual Property (IP) Policy Guidance Note for IMI Applicants and Participants 1. INTRODUCTION The purpose of this guidance note 1 is: - to clarify the IMI IP
More information